The U.S. oxygen concentrator market size was estimated at USD 1.72 Billion in 2025 and is projected to reach USD 3.09 billion by 2033, growing at a CAGR of 7.6% from 2025 to 2033. The increase in the prevalence of respiratory conditions such as COPD, asthma, and sleep apnea, rising healthcare spending, significant investment in R&D, advanced healthcare infrastructure, access to the newest technology, and new product launches.
According to the analyzed Medicare claims data, the Medicare penetration rate for portable oxygen concentrators (POCs) in the U.S. has steadily risen. For instance, in 2021, the POC penetration was 22.0%, while that of stationary was 17%. This is a developing trend favoring portable oxygen concentrators (POCs) over fixed oxygen concentrators and fueling the expansion of the U.S. oxygen concentrator industry.
Government support, such as the Federal Aviation Administration's (FAA) approval of portable concentrators during plane travel, further drives the region's growth. Furthermore, favorable reimbursement policies have enhanced the attractiveness of the U.S. oxygen concentrators market. For instance, in March 2024, a U.S. Congressman introduced the Supplemental Oxygen Access Reform (SOAR) Act to reform and improve access to supplementary oxygen for Medicare beneficiaries. These policies have increased the adoption of oxygen concentrators in the U.S. In addition, rising healthcare spending in the U.S. is driving the demand for effective diagnosis and treatment of respiratory diseases, thereby boosting the market for oxygen concentrators.
The rising prevalence of chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), is a key driver of the U.S. oxygen concentrator market. With COPD affecting over 5% of U.S. adults and contributing to nearly USD 50 billion in annual economic costs, the demand for effective oxygen therapy solutions continues to grow. Long-term oxygen therapy has been clinically proven to improve outcomes in hypoxemic patients, making oxygen concentrators an essential part of disease management.
Moreover, limitations of traditional oxygen delivery methods, such as stationary systems and oxygen cylinders that restrict mobility and require frequent refills, accelerate the shift toward portable oxygen concentrators. These devices provide patients with greater independence and flexibility while addressing the increasing burden of COPD, cystic fibrosis, and heart failure-related hypoxemia, thereby fueling adoption across the U.S. market.
This product will be delivered within 1-3 business days.
According to the analyzed Medicare claims data, the Medicare penetration rate for portable oxygen concentrators (POCs) in the U.S. has steadily risen. For instance, in 2021, the POC penetration was 22.0%, while that of stationary was 17%. This is a developing trend favoring portable oxygen concentrators (POCs) over fixed oxygen concentrators and fueling the expansion of the U.S. oxygen concentrator industry.
Government support, such as the Federal Aviation Administration's (FAA) approval of portable concentrators during plane travel, further drives the region's growth. Furthermore, favorable reimbursement policies have enhanced the attractiveness of the U.S. oxygen concentrators market. For instance, in March 2024, a U.S. Congressman introduced the Supplemental Oxygen Access Reform (SOAR) Act to reform and improve access to supplementary oxygen for Medicare beneficiaries. These policies have increased the adoption of oxygen concentrators in the U.S. In addition, rising healthcare spending in the U.S. is driving the demand for effective diagnosis and treatment of respiratory diseases, thereby boosting the market for oxygen concentrators.
The rising prevalence of chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), is a key driver of the U.S. oxygen concentrator market. With COPD affecting over 5% of U.S. adults and contributing to nearly USD 50 billion in annual economic costs, the demand for effective oxygen therapy solutions continues to grow. Long-term oxygen therapy has been clinically proven to improve outcomes in hypoxemic patients, making oxygen concentrators an essential part of disease management.
Moreover, limitations of traditional oxygen delivery methods, such as stationary systems and oxygen cylinders that restrict mobility and require frequent refills, accelerate the shift toward portable oxygen concentrators. These devices provide patients with greater independence and flexibility while addressing the increasing burden of COPD, cystic fibrosis, and heart failure-related hypoxemia, thereby fueling adoption across the U.S. market.
U.S. Oxygen Concentrator Market Report Segmentation
This report forecasts volume & revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. oxygen concentrator market report based on product, application, and technology:- Product Outlook (Volume, Unit; Revenue, USD Million, 2021-2033)
- Portable Medical Oxygen Concentrators
- Fixed Medical Oxygen Concentrators
- Application Outlook (Volume, Unit; Revenue, USD Million, 2021-2033)
- Home Care
- Non-Home Care
- Technology Outlook (Volume, Unit; Revenue, USD Million, 2021-2033)
- Continuous Flow
- Pulse Flow
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. U.S. Oxygen Concentrator Systems Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Oxygen Concentrator Market: Application Estimates & Trend Analysis
Chapter 6. U.S. Oxygen Concentrator Market: Technology Estimates & Trend Analysis
Chapter 7. U.S. Oxygen Concentrator Market: Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this U.S. Oxygen Concentrator market report include:- espironics (a subsidiary of Koninklijke Philips N.V.) {Effective from January 25, 2024, Philips Respironics halted the sale of their POCs, with end of service scheduled for January 25, 2029.}
- irect Supply
- F Health Products, Inc.
- edaCure Inc.
- idek Medical Products, Inc.
- 2 Concepts
- eact Health
- AIRE Inc. (Acquired by Niterra Co., Ltd., formerly known as NGK SPARK PLUG CO., LTD.)
- eVilbiss Healthcare (a subsidiary of Drive Medical)
- CE Group
- ompass Health Brands
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 90 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.72 Billion |
| Forecasted Market Value ( USD | $ 3.09 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
